Discovery of novel chemotypes for competitive AMPA receptor antagonists as potential antiepileptic agents through structure-based virtual screening of natural products library

  • Pakhuri Mehta
  • Shubham Srivastava
  • Manish Sharma
  • Ruchi MalikEmail author
Original Research


Competitive AMPA receptor antagonists serve as the promising and validated strategy towards the development of novel antiepileptic agents. For this purpose, the structure-based virtual screening approach on library of natural compounds led to the discovery of 11 novel diverse competitive AMPA receptor antagonists with better docking and dG bind scores than the co-crystallized ligand. Validation of the screening protocol was accomplished at three levels like superposition, enrichment, and simulation studies. Involvement of the crucial amino acid interactions such as Thr91 and Arg96 involved in the binding of the co-crystallized ligand was set as the basic criterion for selecting hits on the basis of the ligand–protein interactions. The topmost hit with best dG bind score was subjected to simulation studies, quantum mechanics, and hit optimization study. Computational models developed through validated virtual screening protocol with better pharmacokinetic performance provides in silico evidence towards the development of better therapeutic regime of epilepsy.


Structure-based screening AMPA receptor antagonists ROC Quantum mechanics Epilepsy Molecular dynamics 



Authors are grateful to the Central University of Rajasthan for providing licensed Schrodinger molecular modeling software.


This study was funded by the Department of Science and Technology (INSPIRE fellowship Grant No. DST/INSPIRE/Fellowship/2014/241 and DST-Rajasthan Grant No. L7(3)S&T/R&D/2016/2616).

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Catarzi D, Colotta V, Varano F (2007) Competitive AMPA receptor antagonists. Med Res Rev 27(2):239–278CrossRefGoogle Scholar
  2. 2.
    Meldrum BS, Rogawski MA (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4(1):18–61CrossRefGoogle Scholar
  3. 3.
    Loscher W, Klitgaard H, Twyman RE, Schmidt D (2013) New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 12(10):757–776CrossRefGoogle Scholar
  4. 4.
    Malik R, Mehta P, Srivastava S, Choudhary BS, Sharma M (2016) Structure-based screening, ADMET profiling, and molecular dynamic studies on mGlu2 receptor for identification of newer antiepileptic agents. J Biomol Struct Dyn 35(16):3433–3448CrossRefGoogle Scholar
  5. 5.
    Sarro GD, Gitto R, Russo E, Ibbadu GF, Barreca ML, Luca LD, Chimirri A (2005) AMPA receptor antagonists as potential anticonvulsant drugs. Curr Top Med Chem 5(1):31–42CrossRefGoogle Scholar
  6. 6.
    Kaczor AA, Matosiuk D (2010) Molecular structure of ionotropic glutamate receptors. Curr Med Chem 17(24):2608–2635CrossRefGoogle Scholar
  7. 7.
    Rogawski MA (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11(2):56–63CrossRefGoogle Scholar
  8. 8.
    Russo E, Gitto R, Citraro R, Chimirri A, De Sarro G (2012) New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 21(9):1371–1389CrossRefGoogle Scholar
  9. 9.
    Desos P, Lepagnol JM, Morain P, Lestage P, Cordi AA (1996) Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties. J Med Chem 39(1):197–206CrossRefGoogle Scholar
  10. 10.
    Canton T, Bohme GA, Boireau A, Bordier F, Mignani S, Jimonet P, Jahn G, Alavijeh M, Stygall J, Roberts S, Brealey C, Vuilhorgne M, Debono MW, Guern SL, Laville M, Briet D, Roux M, Stutzmann JM, Pratt J (2001) RPR 119990, a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J Pharmacol Exp Ther 299(1):314–322PubMedGoogle Scholar
  11. 11.
    Mignani S, Bohme GA, Birraux G, Boireau A, Jimonet P, Damour D, Genevois-Borella A, Debono MW, Pratt J, Vuilhorgne M, Wahl F, Stutzmann JM (2002) 9-Carboxymethyl-5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one-2-carbocylic acid (RPR117824): selective anticonvulsive and neuroprotective AMPA antagonist. Bioorg Med Chem 10(5):1627–1637CrossRefGoogle Scholar
  12. 12.
    Koller M, Lingenhoehl K, Schmutz M, Vranesic IT, Kallen J, Auberson YP, Carcache DA, Mattes H, Ofner S, Orain D, Urwyler S (2011) Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity. Bioorg Med Chem Lett 21(11):3358–3361CrossRefGoogle Scholar
  13. 13.
    Orain D, Ofner S, Koller M, Carcache DA, Froestl W, Allgeier H, Rasetti V, Nozulak J, Mattes H, Soldermann N, Floersheim P, Desrayaud S, Kallen J, Lingenhoehl K, Urwyler S (2012) 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists. Bioorg Med Chem Lett 22(2):996–999CrossRefGoogle Scholar
  14. 14.
    Stutzmann JM, Bohme GA, Boireau A, Damour D, Debono MW, Genevois-Borella A, Imperato A, Jimonet P, Pratt J, Randle JCR, Ribeill Y, Vuilhorgne M, Mignani S (2000) 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with in vivo activity. Bioorg Med Chem Lett 10(10):1133–1137CrossRefGoogle Scholar
  15. 15.
    Maestro, Version 10.4 (Epik Version 3.4; Impact Version 6.9; Prime Version 4.2, Glide Version 6.9; LigPrep, Version 3.6; QikProp, Version 4.6). (2015) Schrodinger, LLC, New YorkGoogle Scholar
  16. 16.
    Forge, Version, Cresset, Litlington, Cambridgeshire (UK) Accessed 10 Dec. 2017
  17. 17.
    Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52(7):1757–1768CrossRefGoogle Scholar
  18. 18.
    Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP (2012) Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem Neurosci 3(1):50–68CrossRefGoogle Scholar
  19. 19.
    (2015) SciFinder™, Columbus (OH), American Chemical Society. Accessed 10 Jan. 2018
  20. 20.
    Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP (2011) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(D1):D1100–D1107CrossRefGoogle Scholar
  21. 21.
    Cheeseright T, Mackey M, Rose S, Vinter A (2006) Molecular field Extrema as descriptors of biological activity: definition and validation. J Chem Inf Model 46(2):665–676CrossRefGoogle Scholar
  22. 22.
    Rodrigues T, Reker D, Schneider P, Schneider G (2016) Counting on natural products for drug design. Nat Chem 8(6):531–541CrossRefGoogle Scholar
  23. 23.
    Slon-Usakiewicz J, inventor; Waratah Pharmaceuticals Inc., assignee (2007) Screening methods for amyloid beta modulators. United States Patent US 2,007,134,449Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of PharmacyCentral University of RajasthanAjmerIndia
  2. 2.School of PharmacyMaharishi Markandeshwar UniversityAmbalaIndia

Personalised recommendations